Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis.
메타분석
4/5 보강
TL;DR
To compare the prevalence of AD between patients with either vitiligo or AA and those without these disorders by performing a meta-analysis of observational studies, a fixed-effects model was performed using pooled odds ratios.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: vitiligo and alopecia areata (AA)
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Pooled analysis of 4 studies found higher odds of AD in patients with alopecia totalis or alopecia universalis compared with those with patchy alopecia (OR, 1.22; 95% CI, 1.01-1.48, P = .04). [CONCLUSIONS AND RELEVANCE] Patients with either vitiligo, especially early-onset disease, or AA, especially alopecia totalis or alopecia universalis, have significantly increased risk for AD.
📑 코퍼스 인용 관계
· 인용됨 26
📑 인용한 논문 (6) ▾
- Cutaneous and Gut Dysbiosis in Alopecia Areata: A Review. JID innovations : skin science from molecules to population health · 2025
- Global Burden of Alopecia Areata and Associated Diseases: A Trend Analysis From 1990 to 20… Journal of cosmetic dermatology · 2025
- Increased risk of incident alopecia areata among patients with hidradenitis suppurativa: A… Biomedical journal · 2025
- Association between non-scarring alopecia and hypothyroidism: a bidirectional two-sample M… Frontiers in endocrinology · 2024
- Paediatric alopecia areata cases in a tertiary institution in Singapore: a retrospective r… Singapore medical journal · 2024
- Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata … Frontiers in immunology · 2024
연도별 인용 (2015–2026) · 합계 195
OpenAlex 토픽 ·
melanin and skin pigmentation
Dermatology and Skin Diseases
Mast cells and histamine
Abstract 🌐 Abstract
[IMPORTANCE] Previous studies found conflicting results as to whether atopic dermatitis (AD) is increased in patients with vitiligo and alopecia areata (AA).
[OBJECTIVE] To compare the prevalence of AD between patients with either vitiligo or AA and those without these disorders by performing a meta-analysis of observational studies.
[DATA SOURCES] MEDLINE, EMBASE, Cochrane Library, Google Scholar, and a manual search of 12 additional journals between 1946 and April 5, 2014.
[STUDY SELECTION] Observational studies published in any language that compared the prevalence of AD among patients with and without either vitiligo or AA.
[DATA EXTRACTION AND SYNTHESIS] Data were extracted by 2 independent investigators. Quality of evidence was assessed using the Newcastle-Ottawa Scale and Methodological Evaluation of Observational Research checklist. A meta-analysis of studies assessing AD, vitiligo, and/or AA was performed using a fixed-effects model to estimate pooled odds ratios (ORs). Subset analyses were performed for childhood vs adult-onset vitiligo and alopecia totalis or alopecia universalis vs patchy alopecia.
[MAIN OUTCOMES AND MEASURES] Self-reported and/or physician-diagnosed AD, vitiligo, and AA.
[RESULTS] In total, 16 studies of vitiligo and 17 studies of AA were included in the review. In the pooled analysis of the studies that included control patients without vitiligo (n = 2) and control patients without AA (n = 3), patients with vitiligo (Cochran-Mantel-Haenszel OR, 7.82; 95% CI, 3.06-20.00, P < .001) or AA (OR, 2.57; 95% CI, 2.25-2.94, P < .001) had significantly higher odds of AD than did control patients without these disorders. Pooled analysis of 3 studies found higher odds of AD in patients with early-onset vitiligo (<12 years) compared with those with late-onset vitiligo (OR, 3.54; 95% CI, 2.24-5.63, P < .001). Pooled analysis of 4 studies found higher odds of AD in patients with alopecia totalis or alopecia universalis compared with those with patchy alopecia (OR, 1.22; 95% CI, 1.01-1.48, P = .04).
[CONCLUSIONS AND RELEVANCE] Patients with either vitiligo, especially early-onset disease, or AA, especially alopecia totalis or alopecia universalis, have significantly increased risk for AD.
[OBJECTIVE] To compare the prevalence of AD between patients with either vitiligo or AA and those without these disorders by performing a meta-analysis of observational studies.
[DATA SOURCES] MEDLINE, EMBASE, Cochrane Library, Google Scholar, and a manual search of 12 additional journals between 1946 and April 5, 2014.
[STUDY SELECTION] Observational studies published in any language that compared the prevalence of AD among patients with and without either vitiligo or AA.
[DATA EXTRACTION AND SYNTHESIS] Data were extracted by 2 independent investigators. Quality of evidence was assessed using the Newcastle-Ottawa Scale and Methodological Evaluation of Observational Research checklist. A meta-analysis of studies assessing AD, vitiligo, and/or AA was performed using a fixed-effects model to estimate pooled odds ratios (ORs). Subset analyses were performed for childhood vs adult-onset vitiligo and alopecia totalis or alopecia universalis vs patchy alopecia.
[MAIN OUTCOMES AND MEASURES] Self-reported and/or physician-diagnosed AD, vitiligo, and AA.
[RESULTS] In total, 16 studies of vitiligo and 17 studies of AA were included in the review. In the pooled analysis of the studies that included control patients without vitiligo (n = 2) and control patients without AA (n = 3), patients with vitiligo (Cochran-Mantel-Haenszel OR, 7.82; 95% CI, 3.06-20.00, P < .001) or AA (OR, 2.57; 95% CI, 2.25-2.94, P < .001) had significantly higher odds of AD than did control patients without these disorders. Pooled analysis of 3 studies found higher odds of AD in patients with early-onset vitiligo (<12 years) compared with those with late-onset vitiligo (OR, 3.54; 95% CI, 2.24-5.63, P < .001). Pooled analysis of 4 studies found higher odds of AD in patients with alopecia totalis or alopecia universalis compared with those with patchy alopecia (OR, 1.22; 95% CI, 1.01-1.48, P = .04).
[CONCLUSIONS AND RELEVANCE] Patients with either vitiligo, especially early-onset disease, or AA, especially alopecia totalis or alopecia universalis, have significantly increased risk for AD.
- 표본수 (n) 2
- p-value P < .001
- 95% CI 3.06-20.00
- 연구 설계 meta-analysis
To compare the prevalence of AD between patients with either vitiligo or AA and those without these disorders by performing a meta-analysis of observational studies, a fixed-effects model was performe
APA 7
Mohan, G. C., & Silverberg, J. I. (2015). Association of vitiligo and alopecia areata with atopic dermatitis: A systematic review and meta-analysis.. JAMA dermatology, 151(5), 522-8. https://doi.org/10.1001/jamadermatol.2014.3324
Vancouver
Mohan GC, Silverberg JI. Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis. JAMA dermatology. 2015;151(5):522-8. doi:10.1001/jamadermatol.2014.3324
AMA 11
Mohan GC, Silverberg JI. Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis. JAMA dermatology. 2015;151(5):522-8. doi:10.1001/jamadermatol.2014.3324
Chicago
Mohan, G. C., and Silverberg, J. I.. 2015. "Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis." JAMA dermatology 151 (5): 522-8. https://doi.org/10.1001/jamadermatol.2014.3324
MLA 9
Mohan, G. C., and Silverberg JI. "Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis." JAMA dermatology, vol. 151, no. 5, 2015, pp. 522-8. doi:10.1001/jamadermatol.2014.3324.
PMID
25471826 ↗
추출된 의학 개체 (NER)
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 5/8 (63%)
· 참조 0편 · 후속 5편
이 논문을 인용한 후속 연구 20
- Alopecia areata.
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
- Prevalence and Risk Factors Associated with the Occurrence of Autoimmune Diseases in Patients with A…
- How Our Microbiome Influences the Pathogenesis of Alopecia Areata.
- New and Emerging Therapies for Alopecia Areata.
- Cumulative Life Course Impairment of Alopecia Areata.
- Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab.
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib.
- Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2.
- Association among Thyroid Dysfunction, Asthma, Allergic Rhinitis and Eczema in Children with Alopeci…
- Stratification of alopecia areata reveals involvement of CD4 T cell populations and altered faecal m…
- Retrospective evaluation of clinical profile and comorbidities in patients with alopecia areata.
- Global Burden of Alopecia Areata and Associated Diseases: A Trend Analysis From 1990 to 2021.
- Association of atopic dermatitis with autoimmune diseases: A bidirectional and multivariable two-sam…
- Dupilumab for the treatment of alopecia areata in children with atopic dermatitis.
- Co-regulatory mechanisms and potential markers of oxidative stress-related genes in vitiligo and alo…
- Associations between season, climate, and pediatric alopecia areata flares in Providence, Rhode Isla…
- Remission of Alopecia Universalis after 1 Year of Treatment with Dupilumab in a Patient with Severe …
- Cutaneous and Gut Dysbiosis in Alopecia Areata: A Review.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Alopecia areata.
TL;DRAlopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the…
-
Epidemiology and burden of alopecia areata: a systematic review.
TL;DRAA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approxi…
-
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
TL;DRIn two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Hair follicle immune privilege and its collapse in alopecia areata.
TL;DRA key goal for effective AA management is the re‐establishment of a functional HF IP, which will also provide superior protection from disease relapse, and may confer increased sus…